Clinical Trials at Duke Comprehensive Cancer Center

If you need additional information about any of the trials listed or would like to inquire about other open trials, please contact (919) 684-5301 or visit The Preston Robert Tisch Brain Tumor Center at Duke.

Trial Phase Brain Cancer
00006677 I Recurrent GBM Stem Cell Tumor Amplified RNA Immunotherapy Trial
00006870 II Phase II Single-Arm Study of Pre-Operative Stereotactic Radiosurgery for Brain Metastases
00011617 I A Phase I Study of Immunotoxin, MR1-1
00013436 II A Phase II Study of TLN-4601 in Patients with Glioblastoma Multiforme (TLN-4601-201)
00014101 I A Phase I Study of MK-0752 in Pediatric Patients with Recurrent or Refractory CNS Malignancies
00016989 II A Phase II Study of XL184 in Subject with Progressive or Recurrent Glioblastoma Multiforme in First or Second Relapse
00017381 II Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma
00000393 I Phase I Study of Zactima (ZD6474) Plus Imatinib Mesylate and Hydroxyurea for Patients with Recurrent Malignant Glioma
00007559 I Pilot Study of Dronabinol for Adult Patients with Primary Gliomas
00000305 II A Phase II, Multicenter, Open-Label Case-Controlled (Part 1), Randomized, Active-controlled (Part 2) Study of AQ4N, in Combination with Radiotherapy and Temozolomide, for Safety, Tolerability and Activity in Subjects with newly Diagnosed Glioblastoma Mult
00003877 N/A ATTAC: Anti-Tumor Immunotherapy Targeted Against Cytomegalovirus in Patients with Newly Diagnosed Glioblastoma Multiforme During Recovery from Therapeutic Temozolomide-Induced Lymphopenia
00000581 I REGULATory T-Cell Inhibition with Daclizumab (Zenapaxr) during Recovery from Therapeutic Temozolomide-induced Lymphopenia during Antitumor Immunotherapy Targeted against Cytomegalovirus in Patients with Newly-Diagnosed Glioblastoma Multiforme
00008082 II A Phase II, Multicenter, Randomized, Non-Comparative Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab Alone or In Combination with Irinotecan for Treatment of Glioblastoma Multiforme in First or Second Relapse
00000279 II A Multicenter, Open-Label, Single Agent, Two-Stage Phase II Study to Evaluate the Efficacy and Safety of AMG 102 in Subjects with Advanced Malignant Gliomas
00000404 II Avastin in Combination with Metronomic Temozolomide for Recurrent Malignant Glioma
00000345 II Phase II Trial of Erlotinib plus Sirolimus for Patients with Recurrent Malignant Gliobastoma Multiforme
00011613 II A Biomarker and Phase II Study of GW572016 in Recurrent Malignant Glioma
00012498 II A Single-Center, Open-Label, Phase II, Safety, Pharmacokinetic and Efficacy Study of Panzem Nanocrystal Colloidal Dispersion Administered Orally to Patients with Recurrent Glioblastoma Multiforme
00000220 II Open-label Phase II Trial of Bevacizumab Plus Erlotinib for Patients with Recurrent Malignant Glioma
00004901 II A phase II, open-label, multi-centre, single-arm study, evaluating the efficacy of Glivec plus Hydroxyurea in patients with progressive glioblastoma multiforme (GBM), not receiving enzyme inducing anticonvulsant drugs (EIACDs)
00004710 II A phase II, open-label, multi-centre, single-arm study, evaluating the efficacy of Glivec plus Hydroxyurea in patients with progressive glioblastoma multiforme (GBM), receiving enzyme inducing anticonvulsant drugs (EIACDs) CST157H2202
00000464 II Phase II Study of Sorafenib plus Protracted Temozolomide in Recurrent Glioblastoma Multiforme
00006768 II A Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients with Recurrent/Progressive Meningioma
Duke Comprehensive Cancer Center Accolades